Researchers at the University of California San Diego School of Medicine have identified a previously unknown biological pathway that contributes to high cholesterol. This pathway, which involves a protein called Ral and an enzyme called cathepsin A (CTSA), reduces the number of LDL receptors on liver cells, making it harder for the body to remove harmful cholesterol from the bloodstream. The team discovered that consuming high amounts of dietary cholesterol activates Ral, leading to a chain of events that results in the loss of LDL receptors. They also found that blocking CTSA with a small molecule inhibitor increased the stability of LDL receptors and significantly lowered circulating LDL cholesterol levels in mice. This breakthrough could lead to the development of a new treatment for high cholesterol, particularly for patients who do not respond well to existing medications. The researchers have identified an experimental drug that has already undergone safety testing in humans and may be ready to advance into a Phase 2 clinical trial to investigate its effectiveness against high cholesterol. The discovery of this new pathway and the potential treatment offers new hope for individuals struggling to lower their cholesterol levels. Further research is needed to confirm the effectiveness of the treatment, but this finding has the potential to revolutionize the way we approach high cholesterol treatment.